ArticleAntibiotics (Basel, Switzerland)2024
Study of the Antimicrobial Activity of the Human Peptide SQQ30 against Pathogenic Bacteria.
Article in Antibiotics (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 11 citations in OpenAlex.
- Article
- Phytochemistry, Antimicrobial, and Antibiofilm Properties of MalagasyPlants (Basel, Switzerland) · 2026Article
- Myristicin fromAntibiotics (Basel, Switzerland) · 2026Article
- Study of Human Antimicrobial Peptides Active Against Some Bacteroidota Species of the Oral Cavity.Antibiotics (Basel, Switzerland) · 2026Article
- Design of 3D Additive Manufactured Hybrid Scaffolds for Periodontal Repair Strategies.ACS applied bio materials · 2025Article
- South Tyrol (Italy)Molecules (Basel, Switzerland) · 2025Article
- A review on the screening methods for the discovery of natural antimicrobial peptides.Journal of pharmaceutical analysis · 2025Review
- Antimicrobial Activity and Mode of Action of N-Heterocyclic Carbene Silver(I) Complexes.Molecules (Basel, Switzerland) · 2024Article
- Biological Properties of Oleanolic Acid Derivatives Bearing Functionalized Side Chains at C-3.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Given the continuous increase in antibiotic resistance, research has been driven towards the isolation of new antimicrobial molecules. Short, charged, and very hydrophobic antimicrobial peptides have a direct action against biological membranes, which are less prone to developing resistance. Using a bioinformatic tool, we chose the SQQ30 peptide, isolated from the human SOGA1 protein. The antimicrobial activity of this peptide against various Gram-negative and Gram-positive bacterial strains and against a fungal strain was studied. A mechanism of action directed against biological membranes was outlined. When administered in combination with the antibiotic ciprofloxacin and with the TRS21 (buforin II), another antimicrobial peptide, SQQ30 can be used with a lower MIC, showing additivity and synergism, respectively. Particularly interesting is the ability of SQQ30 to bind LPS in Gram-negative strains, preventing the eukaryotic cell from releasing inflammatory mediators. Our study indicates SQQ30 as a novel and promising antimicrobial agent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.